Fenretinide for COVID-19: real-time analysis

Download Image

Post

c19early.org

Fenretinide for COVID-19

1 study with 351 patients

Serious outcome risk

Fenretinide

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Fenretinide studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−44%

Mortality (1)−44%

RCTs (1)−44%

Late (1)−44%

00.511.5+

← Fenretinide
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Fenretinide (LAU-7b) is an oral small molecule host-directed therapy that targets host cell membrane lipid pathways to exert antiviral and inflammation-resolving effects.


May 30 2024	Houle et al., NCT04417257	RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
May 30 2024	44% higher mortality (p=0.34). RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b).